Comments

BioMarin Pharmaceutical Analyst Ratings

BMRNNASDAQ
Logo brought to you by Benzinga Data
Trade with Public
Trade with Public
$57.18
0.410.72%
At close: Jan 22, 4:00 PM EST
$57.52
0.340.59%
After Hours: 6:37 PM EST
OverviewNewsEarningsOptionsGuidance

Analyst Ratings

Insider TradesShort InterestGovernment TradesStock Report
Consensus Rating1
Buy
Highest Price Target1
$140.00
Lowest Price Target1
$60.00
Consensus Price Target1
$93.82

BioMarin Pharmaceutical Analyst Ratings and Price Targets | NASDAQ:BMRN | Benzinga

BioMarin Pharmaceutical Inc has a consensus price target of $93.82 based on the ratings of 30 analysts. The high is $140 issued by Truist Securities on September 25, 2023. The low is $60 issued by HC Wainwright & Co. on December 22, 2025. The 3 most-recent analyst ratings were released by Canaccord Genuity, Truist Securities, and HC Wainwright & Co. on January 20, 2026, December 23, 2025, and December 22, 2025, respectively. With an average price target of $86 between Canaccord Genuity, Truist Securities, and HC Wainwright & Co., there's an implied 49.51% upside for BioMarin Pharmaceutical Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

6
1
Oct 25
1
Nov 25
1
2
Dec 25
1
Jan
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Canaccord Genuity
Truist Securities
HC Wainwright & Co.
Leerink Partners
Stifel

1calculated from analyst ratings

Analyst Ratings for BioMarin Pharmaceutical

Buy NowGet Alert
01/20/2026Buy Now70.38%Canaccord Genuity$84 → $98UpgradeHold → BuyGet Alert
12/23/2025Buy Now73.85%Truist Securities$80 → $100MaintainsBuyGet Alert
12/22/2025Buy Now4.31%HC Wainwright & Co.$55 → $60MaintainsNeutralGet Alert
12/03/2025Buy Now4.31%Leerink Partners$82 → $60DowngradeOutperform → Market PerformGet Alert
11/06/2025Buy Now6.05%Stifel$73 → $61DowngradeBuy → HoldGet Alert
11/03/2025Buy Now52.99%Bernstein$95 → $88MaintainsOutperformGet Alert
10/28/2025Buy Now39.08%Truist Securities$90 → $80MaintainsBuyGet Alert
10/28/2025Buy Now21.7%Wells Fargo$90 → $70MaintainsOverweightGet Alert
10/28/2025Buy Now26.91%Stifel$91 → $73MaintainsBuyGet Alert
10/28/2025Buy Now39.08%Barclays$86 → $80MaintainsOverweightGet Alert
10/28/2025Buy Now70.38%Morgan Stanley$104 → $98MaintainsOverweightGet Alert
10/27/2025Buy Now-4.38%HC Wainwright & Co.$60 → $55MaintainsNeutralGet Alert
10/09/2025Buy Now106.88%JP Morgan$116 → $119MaintainsOverweightGet Alert
09/08/2025Buy Now4.31%HC Wainwright & Co. → $60Initiates → NeutralGet Alert
08/06/2025Buy Now84.28%Guggenheim$101 → $106MaintainsBuyGet Alert
08/05/2025Buy Now98.19%UBS$113 → $114MaintainsBuyGet Alert
07/22/2025Buy Now66.9%Morgan Stanley$97 → $96MaintainsOverweightGet Alert
07/14/2025Buy Now96.45%JP Morgan$108 → $113MaintainsOverweightGet Alert
05/05/2025Buy Now80.81%Goldman Sachs$124 → $104MaintainsBuyGet Alert
05/02/2025Buy Now35.61%Citigroup$82 → $78MaintainsNeutralGet Alert
02/24/2025Buy Now70.38%Oppenheimer → $98UpgradePerform → OutperformGet Alert
02/20/2025Buy Now39.08%Scotiabank$78 → $80MaintainsSector PerformGet Alert
02/20/2025Buy Now42.56%Citigroup$81 → $82MaintainsNeutralGet Alert
02/20/2025Buy Now21.7%RBC Capital$70 → $70ReiteratesSector Perform → Sector PerformGet Alert
02/20/2025Buy Now56.47%Cantor Fitzgerald$90 → $90ReiteratesOverweight → OverweightGet Alert
02/20/2025Buy Now96.45%UBS$109 → $113MaintainsBuyGet Alert
02/20/2025Buy Now119.05%Piper Sandler$122 → $126MaintainsOverweightGet Alert
02/20/2025Buy Now79.07%B of A Securities$99 → $103MaintainsBuyGet Alert
12/12/2024Buy Now56.47%Cantor Fitzgerald$90 → $90ReiteratesOverweight → OverweightGet Alert
11/15/2024Buy Now65.16%Wolfe Research → $95Initiates → OutperformGet Alert
10/30/2024Buy Now40.82%Citigroup$93 → $81MaintainsNeutralGet Alert
10/30/2024Buy Now46.04%Canaccord Genuity$93 → $84MaintainsHoldGet Alert
10/30/2024Buy Now56.47%Cantor Fitzgerald$110 → $90MaintainsOverweightGet Alert
10/30/2024Buy Now89.5%JP Morgan$110 → $109MaintainsOverweightGet Alert
10/30/2024Buy Now39.08%RBC Capital$80 → $80ReiteratesSector Perform → Sector PerformGet Alert
10/30/2024Buy Now82.55%Evercore ISI Group$115 → $105MaintainsOutperformGet Alert
10/30/2024Buy Now84.28%UBS$104 → $106MaintainsBuyGet Alert
10/30/2024Buy Now13%Baird$72 → $65MaintainsNeutralGet Alert
10/30/2024Buy Now—William Blair—DowngradeOutperform → Market PerformGet Alert
10/10/2024Buy Now37.34%Raymond James → $79Reinstates → OutperformGet Alert
10/04/2024Buy Now39.08%RBC Capital$85 → $80MaintainsSector PerformGet Alert
10/04/2024Buy Now49.51%Barclays$110 → $86MaintainsOverweightGet Alert
09/17/2024Buy Now35.61%Scotiabank$95 → $78MaintainsSector PerformGet Alert
09/17/2024Buy Now56.47%Truist Securities$118 → $90MaintainsBuyGet Alert
09/17/2024Buy Now56.47%Wells Fargo$115 → $90MaintainsOverweightGet Alert
09/17/2024Buy Now47.77%RBC Capital$100 → $85MaintainsSector PerformGet Alert
09/17/2024Buy Now99.93%B of A Securities$130 → $115MaintainsBuyGet Alert
09/17/2024Buy Now51.25%Stifel$115 → $87MaintainsBuyGet Alert
09/17/2024Buy Now56.47%Bernstein$116 → $90MaintainsOutperformGet Alert
09/13/2024Buy Now61.68%Canaccord Genuity$93 → $93MaintainsHoldGet Alert
09/09/2024Buy Now91.24%Cantor Fitzgerald$110 → $110ReiteratesOverweight → OverweightGet Alert
09/05/2024Buy Now108.62%JP Morgan$111 → $120MaintainsOverweightGet Alert
09/05/2024Buy Now73.85%RBC Capital$100 → $100ReiteratesSector Perform → Sector PerformGet Alert
09/05/2024Buy Now65.16%Scotiabank$86 → $95MaintainsSector PerformGet Alert
09/05/2024Buy Now105.15%Truist Securities$140 → $118MaintainsBuyGet Alert
09/05/2024Buy Now112.1%Piper Sandler$107 → $122MaintainsOverweightGet Alert
08/27/2024Buy Now86.02%Piper Sandler$107 → $107MaintainsOverweightGet Alert
08/21/2024Buy Now99.93%Stifel$112 → $115MaintainsBuyGet Alert
08/20/2024Buy Now91.24%Bernstein$94 → $110UpgradeMarket Perform → OutperformGet Alert
08/06/2024Buy Now108.62%TD Cowen$125 → $120MaintainsBuyGet Alert
08/06/2024Buy Now49.51%Scotiabank$85 → $86MaintainsSector PerformGet Alert
08/06/2024Buy Now94.71%Stifel$108 → $112MaintainsBuyGet Alert
08/06/2024Buy Now73.85%RBC Capital$100 → $100ReiteratesSector Perform → Sector PerformGet Alert
08/06/2024Buy Now91.24%Barclays$111 → $110MaintainsOverweightGet Alert
08/06/2024Buy Now99.93%Evercore ISI Group$113 → $115MaintainsOutperformGet Alert
08/05/2024Buy Now91.24%Cantor Fitzgerald$110 → $110ReiteratesOverweight → OverweightGet Alert
07/25/2024Buy Now54.73%Canaccord Genuity$89 → $89MaintainsHoldGet Alert
07/22/2024Buy Now91.24%Cantor Fitzgerald$110 → $110ReiteratesOverweight → OverweightGet Alert
06/27/2024Buy Now99.93%Wells Fargo$110 → $115MaintainsOverweightGet Alert
05/17/2024Buy Now25.17%Baird$104 → $72DowngradeOutperform → NeutralGet Alert
05/14/2024Buy Now96.45%Evercore ISI Group → $113Initiates → OutperformGet Alert
04/26/2024Buy Now94.71%Morgan Stanley$115 → $112MaintainsOverweightGet Alert
04/26/2024Buy Now54.73%Canaccord Genuity$91 → $89MaintainsHoldGet Alert
04/25/2024Buy Now91.24%Cantor Fitzgerald$110 → $110ReiteratesOverweight → OverweightGet Alert
04/25/2024Buy Now58.21%Citigroup$94 → $91MaintainsNeutralGet Alert
04/25/2024Buy Now47.77%Scotiabank$83 → $85MaintainsSector PerformGet Alert
04/25/2024Buy Now91.24%Wells Fargo$100 → $110MaintainsOverweightGet Alert
02/29/2024Buy Now58.21%Canaccord Genuity → $91ReiteratesHold → HoldGet Alert
02/23/2024Buy Now73.85%Cantor Fitzgerald$100 → $100ReiteratesOverweight → OverweightGet Alert
02/23/2024Buy Now73.85%RBC Capital$100 → $100ReiteratesSector Perform → Sector PerformGet Alert
02/23/2024Buy Now86.02%Piper Sandler$115 → $107MaintainsOverweightGet Alert
01/30/2024Buy Now80.81%Baird$127 → $104MaintainsOutperformGet Alert
12/21/2023Buy Now75.59%Stifel$101 → $101ReiteratesBuy → BuyGet Alert
11/07/2023Buy Now73.85%RBC Capital$100 → $100ReiteratesSector Perform → Sector PerformGet Alert
11/03/2023Buy Now73.85%BMO Capital$102 → $100MaintainsOutperformGet Alert
11/02/2023Buy Now99.93%Piper Sandler$125 → $115MaintainsOverweightGet Alert
11/02/2023Buy Now103.41%Morgan Stanley$125 → $117MaintainsOverweightGet Alert
11/02/2023Buy Now92.98%Barclays$125 → $111MaintainsOverweightGet Alert
11/02/2023Buy Now73.85%Cantor Fitzgerald$120 → $100MaintainsOverweightGet Alert
11/01/2023Buy Now75.59%Stifel$108 → $101MaintainsBuyGet Alert
10/23/2023Buy Now42.56%Bernstein → $82UpgradeUnderperform → Market PerformGet Alert
10/16/2023Buy Now108.62%Cantor Fitzgerald → $120ReiteratesOverweight → OverweightGet Alert
09/28/2023Buy Now—Raymond James—Initiates → Market PerformGet Alert
09/25/2023Buy Now143.39%Truist Securities → $140ReiteratesBuy → BuyGet Alert
09/18/2023Buy Now108.62%UBS → $120Initiates → BuyGet Alert
09/15/2023Buy Now143.39%Truist Securities → $140ReiteratesBuy → BuyGet Alert
09/14/2023Buy Now108.62%Cantor Fitzgerald → $120ReiteratesOverweight → OverweightGet Alert
09/13/2023Buy Now91.24%Guggenheim → $110ReiteratesBuy → BuyGet Alert
09/13/2023Buy Now73.85%RBC Capital → $100ReiteratesSector Perform → Sector PerformGet Alert
09/13/2023Buy Now108.62%Cantor Fitzgerald → $120ReiteratesOverweight → OverweightGet Alert

FAQ

Q

What is the target price for BioMarin Pharmaceutical (BMRN) stock?

A

The latest price target for BioMarin Pharmaceutical (NASDAQ:BMRN) was reported by Canaccord Genuity on January 20, 2026. The analyst firm set a price target for $98.00 expecting BMRN to rise to within 12 months (a possible 70.38% upside). 28 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioMarin Pharmaceutical (BMRN)?

A

The latest analyst rating for BioMarin Pharmaceutical (NASDAQ:BMRN) was provided by Canaccord Genuity, and BioMarin Pharmaceutical upgraded their buy rating.

Q

When was the last upgrade for BioMarin Pharmaceutical (BMRN)?

A

The last upgrade for BioMarin Pharmaceutical Inc happened on January 20, 2026 when Canaccord Genuity raised their price target to $98. Canaccord Genuity previously had a hold for BioMarin Pharmaceutical Inc.

Q

When was the last downgrade for BioMarin Pharmaceutical (BMRN)?

A

The last downgrade for BioMarin Pharmaceutical Inc happened on December 3, 2025 when Leerink Partners changed their price target from $82 to $60 for BioMarin Pharmaceutical Inc.

Q

When is the next analyst rating going to be posted or updated for BioMarin Pharmaceutical (BMRN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioMarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioMarin Pharmaceutical was filed on January 20, 2026 so you should expect the next rating to be made available sometime around January 20, 2027.

Q

Is the Analyst Rating BioMarin Pharmaceutical (BMRN) correct?

A

While ratings are subjective and will change, the latest BioMarin Pharmaceutical (BMRN) rating was a upgraded with a price target of $84.00 to $98.00. The current price BioMarin Pharmaceutical (BMRN) is trading at is $57.52, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch

Avidity Biosciences Inc
NASDAQ:RNA
$72.74
%
Exact Sciences Corp
NASDAQ:EXAS
$102.37
%
Cogent Biosciences Inc
NASDAQ:COGT
$39.53
%
Neurocrine Biosciences Inc
NASDAQ:NBIX
$137.37
%
Ionis Pharmaceuticals Inc
NASDAQ:IONS
$81.79
%
Roivant Sciences Ltd
NASDAQ:ROIV
$23.10
0.57%
United Therapeutics Corp
NASDAQ:UTHR
$472.06
%
Vaxcyte Inc
NASDAQ:PCVX
$54.00
0.32%
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved